Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine ...
11/16 patients in Evaxion's phase 2 trial showed 69% Overall Response Rate with tumor reduction in 15/16 patients. Full data to be presented at ESMO 2024 and discussed in a webinar with Professor Georgina V. Long on September 18, 2024.
Related Clinical Trials
Reference News
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine ...
11/16 patients in Evaxion's phase 2 trial showed 69% Overall Response Rate with tumor reduction in 15/16 patients. Full data to be presented at ESMO 2024 and discussed in a webinar with Professor Georgina V. Long on September 18, 2024.